Bicycle Therapeutics (NASDAQ:BCYC) Stock: Insider Robert Charles Swanton Sells 3,431 Shares

Bicycle Therapeutics PLC Sponsored ADR (NASDAQ:BCYC) Director Robert Swanton sold 3,431 shares of the firm’s stock in a transaction that occurred on Friday, October 2nd. The shares were sold at an average price of $3.47, for a total value of $11,905.57. Following the completion of the sale, the director directly owned 15,782 shares in the company, valued at approximately $54,763.54. The trade was a 17.86% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Bicycle Therapeutics Stock Down 5.5%

Shares of BCYC stock traded down $0.22 during trading hours on Tuesday, hitting $3.79. 620,678 shares of the company’s stock were exchanged, compared to its average volume of 422,826. The firm has a market cap of $265.27 million, a P/E ratio of -1.39 and a beta of 1.68. The firm has a 50 day moving average of $3.96 and a two-hundred day moving average of $4.31. Bicycle Therapeutics PLC Sponsored ADR has a fifty-two week low of $3.33 and a fifty-two week high of $9.16.

Bicycle Therapeutics (NASDAQ:BCYC) last released its quarterly earnings results on Thursday, July 30th. The company reported ($0.72) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.58) by ($0.14). The company had revenue of $0.63 million during the quarter, compared to analyst estimates of $4.22 million. Bicycle Therapeutics had a negative net margin of 311.11% and a negative return on equity of 33.22%. On average, equities analysts forecast that Bicycle Therapeutics PLC Sponsored ADR will post -2.26 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Bicycle Therapeutics

A number of institutional investors have recently bought and sold shares of BCYC. GAMMA Investing LLC boosted its holdings in Bicycle Therapeutics by 512.9% in the 2nd quarter. GAMMA Investing LLC now owns 7,704 shares of the company’s stock valued at $33,000 after purchasing an additional 6,447 shares during the last quarter. Portland Investment Counsel Inc. acquired a new stake in shares of Bicycle Therapeutics during the 2nd quarter worth approximately $64,000. Royal Bank of Canada increased its holdings in shares of Bicycle Therapeutics by 35.5% during the 1st quarter. Royal Bank of Canada now owns 14,470 shares of the company’s stock worth $67,000 after buying an additional 3,788 shares during the last quarter. R Squared Ltd purchased a new stake in shares of Bicycle Therapeutics during the 1st quarter valued at approximately $98,000. Finally, FNY Investment Advisers LLC raised its position in shares of Bicycle Therapeutics by 247.4% during the 2nd quarter. FNY Investment Advisers LLC now owns 26,250 shares of the company’s stock valued at $111,000 after buying an additional 18,693 shares during the period. 86.15% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several research analysts recently weighed in on the stock. Weiss Ratings restated a “sell (e+)” rating on shares of Bicycle Therapeutics in a research report on Wednesday, July 8th. Wall Street Zen upgraded Bicycle Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Saturday, August 15th. Finally, Needham & Company LLC decreased their target price on Bicycle Therapeutics from $15.00 to $14.00 and set a “buy” rating on the stock in a research report on Thursday, July 30th. Five equities research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $13.86.

Bicycle Therapeutics Company Profile

Bicycle Therapeutics plc (NASDAQ:BCYC) is a clinical-stage biotechnology company developing medicines based on its proprietary Bicycle molecule platform. The platform uses short, chemically constrained peptides designed to bind selectively to biological targets, with the goal of combining the tissue penetration and target specificity of small molecules with some of the binding characteristics of larger biologic medicines.

The company is focused primarily on oncology and is developing Bicycle toxin conjugates, immune-cell engaging molecules and other targeted therapeutics.